NCCN now recognizes BCG-unresponsive papillary-only NMIBC as eligible for nogapendekin plus BCG, broadening access beyond the ...
For decades, cancer immunotherapy has focused primarily on CD8+ cytotoxic T lymphocytes as the main executors of tumor cell ...
T Cells Gain Phagocytic Function via Specific Antigen RecognitionThe research team engineered CD8+ Jurkat T cells to express SVAR16 ...
The COVID-19 pandemic brought messenger RNA (mRNA) vaccines to the forefront of global health care. After their clinical trial stages, the first COVID-19 mRNA vaccine was administered on 8 December ...
CD4+ T cells, long regarded as supporting actors in cancer immunity, are emerging as central regulators of tumor control and ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer and infectious diseases, today announced a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results